You are here: Industry Insights > Boehringer Ingelheim

News List

Boehringer Ingelheim posts 5-percent sales growth for prescription drugs in 2017; provides R&D update firstwordpharma
April 26, 2018
Boehringer Ingelheim reported Wednesday that sales of prescription medicines in 2017 rose 5 percent year-over-year to 12.6 billion euros ($15.4 billion), with six medicines generating revenue of over $1 billion.
Boehringer Ingelheim and HealthPrize Expand Successful Digital Patient Support Program biospace
April 20, 2018
Boehringer Ingelheim and HealthPrize Technologies today announced the expansion of the RespiPoints digital support program to anyone taking one of several Boehringer Ingelheim medicines
Boehringer Ingelheim Strikes a Series of Investments and Collaborations Worldwide biospace
April 13, 2018
The last week has marked plenty of investment activity in operations, collaborations and PR the last week or two for Ingelheim, Germany-based Boehringer Ingelheim.
Boehringer Ingelheim, OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership americanpharmaceuticalreview
April 09, 2018
Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies
Boehringer Ingelheim and OSE Immunotherapeutics Ink $1.4B Deal biospace
April 08, 2018
Boehringer Ingelheim, headquartered in Ingelheim, Germany, and OSE Immunotherapeutics,based in Nantes, Frances, signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associa biospace
March 20, 2018
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that FDA has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Inspirational patient stories reveal the challenging realities of living with devastating rare disea worldpharmanews
March 13, 2018
Boehringer Ingelheim unveils a new phase of "More Than Scleroderma: The Inside Story", and launches the new patient website www.morethanscleroderma.com.
Inspirational patient stories reveal the challenging realities of living with devastating rare disea worldpharmanews
March 01, 2018
Boehringer Ingelheim unveils a new phase of "More Than Scleroderma: The Inside Story"
Boehringer Ingelheim Refocuses PDE9 Inhibition Brain Research on Schizophrenia americanpharmaceuticalreview
February 12, 2018
These AD trials were part of an extensive clinical trial program exploring the efficacy of compounds which target malfunctioning of specific (glutamatergic) brain circuits as potential new treatments for specific symptoms and traits of mental illness.
HITGEN and Boehringer Ingelheim Enter DNA-Encoded Library Based Drug Discovery Research Collaboratio en-cphi.cn
November 27, 2017
Chengdu, China，November 23rd 2017, HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Boehringer Ingelheim to identify novel small molecule leads for targets of interest to Boehringer Ingelheim.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page